Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc and Pfizer Inc's ViiV Healthcare receives European approval for Tivicay


Tuesday, 21 Jan 2014 06:42am EST 

Glaxosmithkline Plc:Says ViiV Healthcare Ltd (a global specialist HIV company with GlaxoSmithKline, Pfizer Inc. and Shionogi Ltd as shareholders) is issuing ViiV Healthcare's new HIV medicine Tivicay (dolutegravir) is approved in Europe.Says Tivicay, an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.Says Tivicay development programme was comprehensive in its breadth, including people with HIV, as well as those who had already been treated with other HIV medicines and those who were infected with a virus that had developed resistance to previously available integrase inhibitors. 

Company Quote

1562.0
27.5 +1.79%
27 Apr 2015